Bristol Myers details Krazati confirmatory study failure in colorectal cancer on July 07, 2026 Accelerated adagrasib Approved cetuximab Colorectal Carcinoma Confirmatory Trial Frequency of Responses K-ras Oncogene Krazati KRYSTAL-1 Myers Squibb Phase 3 United States Food and Drug Administration +
BeOne Streamlines Oncology Pipeline: Shelves CDK2 and KRAS Inhibitors, Advances Degraders on May 07, 2026 BeOne Medicines CDK2 protein, human degraders K-ras Oncogene Neoplasms pipeline +
Treeline Announces $200M Funding Boost, Moves Three Cancer Drugs into Clinic on September 04, 2025 BCL6 gene cancer drugs Clinical Trials Degrader EZH2 protein, human Funding Inhibitor K-ras Oncogene Lymphoma Series Solid Neoplasm TLN-121 TLN-254 TLN-372 Treeline +
Bayer Expands Oncology Pipeline with $1.3B Kumquat Deal on August 13, 2025 Approved Bayer Cancer Therapeutic Procedure commercialization G12D inhibitor K-ras Oncogene Kumquat Biosciences milestone payments oncology pipeline precision oncology United States Food and Drug Administration +
Revolutions KRAS drugs appear competitive in several lung cancer settings on May 09, 2025 Biological Markers G12C inhibitors K-ras Oncogene Krazati Lumakras Non-Small Cell Lung Carcinoma Rotation sotorasib +
BridgeBio Oncology Therapeutics Goes Public via $450M SPAC Merger on March 03, 2025 Biochemical Pathway BridgeBio cancer pipeline Helix (Snails) inhibitors K-ras Oncogene KRAS merger Neoplasms PI3 K pathway ras Oncogene SPAC +